Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the MyChoice ® CDx ...

In line with guidelines recommending genetic testing for diagnosis of kidney diseases, studies show improved diagnosis and management based on results. Genetic testing for kidney diseases leads to a ...

Guardant Health markets Shield, an FDA-approved blood test for primary colorectal cancer screening. The Harris Poll conducted the survey from Feb. 24-26, 2026, among 1,189 U.S. adults, ages 45 and ...

Genetic testing can be a fearful, daunting, overwhelming, exciting, or joyful experience. In many cases, the emotions of people who pursue genetic testing can be described with more than just one of ...

GeneDx Holdings WGS announced a sponsored genetic testing program with Zevra Therapeutics to improve diagnosis for patients suspected of having Niemann-Pick Disease Type C (NPC), a rare and ...

Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary ...

As the Centers for Medicare and Medicaid Services calls for public feedback on how to stop lab test fraud, experts say a tailored regulatory strategy will be key to avoid stifling innovation.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received CE Mark approval for its Elecsys® Apolipoprotein E4 biomarker test – the first in-vitro diagnostic (IVD) immunoassay to identify ...

To check for possible prostate cancer, physicians most often use prostate-specific antigen (PSA) tests and digital rectal exams (DREs). For a firm diagnosis, they use core needle biopsies. This page ...

Myriad Genetics receives US FDA approval for MyChoice CDx test as companion diagnostic for Zejula for patients with ovarian cancer: Salt Lake City Thursday, March 19, 2026, 15:00 ...